Prediction of Intra-individual Variability in Bioequivalence Studies of 278 Formulations: Comprehensive Analysis Using Physicochemical and Pharmacokinetic Parameters

The purpose of the present study was to predict the intra-individual variability (%CV<sub>intra</sub>) values of C<sub>max</sub> using observed parameters of physicochemical and pharmacokinetic for a variety of formulations. A database was used to summarize the parameters of clinical bioequivalence (BE) studies of oral drugs, including the highest dose tablets, orally disintegrating tablets (ODT), and capsules (278 formulations [238 compounds]). As explanatory variables, %CV<sub>intra</sub>, inter-individual variability (%CV<sub>inter</sub>), absolute bioavailability (BA), T<sub>max</sub>, t<sub>1/2</sub>, dose number (Do), and dissolution rate (D%) were selected. Explanatory variables correlated with %CV<sub>intra</sub> were identified by multivariate analysis and grouped quantitatively by K-means clustering analysis. The %CV<sub>intra</sub> predictions compared three models of multiple regression, boosting tree, and neural network. In the neural network, the coefficient of determination (R<sup>2</sup>) and the root mean square error (RMSE) were the best, with good correlation between the predicted and observed values of the test data (R<sup>2</sup> = 0.69). The explanatory variables used in this study are readily available from the literature of reference formulation and in vitro measurement. Therefore, predicting %CV<sub>intra</sub> for C<sub>max</sub> without conducting pilot studies is useful for clinical planning in the early stages of generic drug development. We believe that we could further contribute to speeding up and reducing the cost of generic drug development.

Authors

Institutions

Publication Details

Journal
Chemical and Pharmaceutical Bulletin
Published
2025-04-09
DOI
https://doi.org/10.1248/cpb.c24-00806
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prediction of Intra-individual Variability in Bioequivalence Studies of 278 Formulations: Comprehensive Analysis Using Physicochemical and Pharmacokinetic Parameters

Masaki Higashino
Chemical and Pharmaceutical Bulletin
Computational Drug Discovery Methods
article

Prediction of Intra-individual Variability in Bioequivalence Studies of 278 Formulations: Comprehensive Analysis Using Physicochemical and Pharmacokinetic Parameters

Masaki Higashino
article en

Abstract

The purpose of the present study was to predict the intra-individual variability (%CV<sub>intra</sub>) values of C<sub>max</sub> using observed parameters of physicochemical and pharmacokinetic for a variety of formulations. A database was used to summarize the parameters of clinical bioequivalence (BE) studies of oral drugs, including the highest dose tablets, orally disintegrating tablets (ODT), and capsules (278 formulations [238 compounds]). As explanatory variables, %CV<sub>intra</sub>, inter-individual variability (%CV<sub>inter</sub>), absolute bioavailability (BA), T<sub>max</sub>, t<sub>1/2</sub>, dose number (Do), and dissolution rate (D%) were selected. Explanatory variables correlated with %CV<sub>intra</sub> were identified by multivariate analysis and grouped quantitatively by K-means clustering analysis. The %CV<sub>intra</sub> predictions compared three models of multiple regression, boosting tree, and neural network. In the neural network, the coefficient of determination (R<sup>2</sup>) and the root mean square error (RMSE) were the best, with good correlation between the predicted and observed values of the test data (R<sup>2</sup> = 0.69). The explanatory variables used in this study are readily available from the literature of reference formulation and in vitro measurement. Therefore, predicting %CV<sub>intra</sub> for C<sub>max</sub> without conducting pilot studies is useful for clinical planning in the early stages of generic drug development. We believe that we could further contribute to speeding up and reducing the cost of generic drug development.

Chemical and Pharmaceutical BulletinVol. 73(4)
Towa Pharmaceutical (Japan) (JP)
Zero hunger
Openalex Percentile: Top 92%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.